Sells RYTELO, a treatment for certain adults with lower-risk myelodysplastic syndromes, to distributors and specialty pharmacies, and develops imetelstat for other blood cancers.
10-K for FY2025, filed Mar 2, 2026We commercially launched RYTELO in the U.S. in June 2024 following its approval by the U.S. Food andView ↗
Drug Administration, or FDA on June 6, 2024 for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes…View ↗
In addition to lower-risk MDS, we are developing imetelstat for the treatment of other myeloid hematologic malignancies. Our Phase 3…View ↗
We distribute RYTELO through third party distributors and specialty pharmacies who are our customers.View ↗
Distributors and specialty pharmacies buy RYTELO; sales are counted when the product is delivered, or when consigned product is removed for shipment to a patient.
10-K for FY2025, filed Mar 2, 2026
FY2025 revenue by product or service ↗$183.9M
10-K for FY2025, filed Mar 2, 2026
$183.9M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Revenues Before Adjustments
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
68% |
Revenues Before Adjustments, FY2025
$223.1M Sources
|
Sold outright |
|
Chargebacks
|
−7.8% |
Chargebacks, FY2025
−$25.5M Sources
|
|
|
Distributor service fees
|
−2.3% |
Distributor service fees, FY2025
−$7.5M Sources
|
|
|
Government Rebates
|
−0.8% |
Government Rebates, FY2025
−$2.6M Sources
|
|
|
Sales Returns And Allowance
|
−1.2% |
Sales Returns And Allowance, FY2025
−$3.8M Sources
|
|
|
Total Gross To Net Adjustments
|
−12% |
Total Gross To Net Adjustments, FY2025
−$39.5M Sources
|
|
|
Product revenues, net
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
56%
FY2022: 0.0%
|
Product revenues, net, FY2025
$183.6M Sources
|
Sold outright |
In the U.S., third-party distributors and specialty pharmacies buy RYTELO and resell it through specialty pharmacy providers to patients and health care providers; insurers and government programs provide coverage and reimbursement. Geron plans to use third parties for commercialization in the EU.
10-K for FY2025, filed Mar 2, 2026We distribute RYTELO through third party distributors and specialty pharmacies who are our customers.View ↗
The third party distributors subsequently resell our product through their related specialty pharmacy providers to patients and health care…View ↗
RYTELO as a monotherapy for the treatment of adult patients with TD anemia due to very low, low or intermediate risk myelodysplastic…View ↗
No. It lost $83.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
$1.4MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and…View ↗
Growing. Revenue grew 132.0x in 4 years, from $1.4M in FY2021 to $183.9M in FY2025, about 239% a year.
From drug development to sales
The older report described imetelstat as investigational and planned possible U.S. commercialization if approved; the latest report says RYTELO has launched in the U.S. and received authorization in the EU.
10-K for FY2022, filed Mar 16, 2023
EU commercialization approach
The older report said Geron might seek partners outside the U.S.; the latest report says it plans to use third parties for EU commercialization rather than commercialize there independently.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 2, 2026If imetelstat is approved in lower risk MDS for marketing by regulatory authorities, we plan to commercialize imetelstat ourselves in the…View ↗
RYTELO as a monotherapy for the treatment of adult patients with TD anemia due to very low, low or intermediate risk myelodysplastic…View ↗
Loading...